Mode
Text Size
Log in / Sign up
Phase 3 N=235 Treatment

Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Post Menopausal Breast Cancer

Enrolled (actual)
235
Serious AEs
31.9%
Results posted
Apr 2020
Primary outcome: Primary: Summary of Number of Participants With Treatment Emergent Adverse Events (TEAE) - All Grades — 4; 0; 4; 195 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
everolimus (Drug); exemestane (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Novartis Pharmaceuticals
Primary completion
Jan 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Summary of Number of Participants With Treatment Emergent Adverse Events (TEAE) - All Grades
4; 0; 4; 195; 36; 231
SECONDARY
Percentage of Participants Response Rates (Best Overall and Overall)
1.5; 0.00; 1.3; 20.1; 8.3; 18.3
SECONDARY
Percentage of Participants Clinical Benefit Rate
48.2; 30.6; 45.5
SECONDARY
Progression Free Survival (PFS)
40.6; 37.0; 40.6
SECONDARY
Percent of Participants Event-free Probability Estimates of Deterioration of Eastern Cooperative Oncology Group (ECOG) Performance Status
100.0; 100.0; 100.00; 95.0; 79.8; 92.7

Summary

This international, multi-center, open-label, single-arm study evaluated the safety and tolerability profile of everolimus in post-menopausal women with HR positive, HER2 negative locally advanced or metastatic breast cancer after documented recurrence or progression following a non-steroidal aromatase inhibitors (NSAI) therapy in Novartis Oncology emergent growth market (EGM) countries.Data was presented by Asian countries vs Non-Asian countries to confirm no difference in safety and efficacy. Summary statistics were presented.

Eligibility Criteria

Inclusion Criteria

  • Postmenopausal women with metastatic, recurrent or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy.
  • Histological or cytological confirmation of hormone-receptor positive (HR+) breast cancer.
  • Disease refractory to non-steroidal aromatase inhibitors, defined as:
  • Recurrence while on, or within 12 months (365 days) of completion of adjuvant therapy with letrozole or anastrozole, or
  • Progression while on, or within one month (30 days) of completion of letrozole or anastrozole treatment for locally advanced or metastatic breast cancer (ABC).
  • Radiological or objective evidence of recurrence or progression on or after the last systemic therapy prior to enrolment.
  • Patients must have had:
  • At least one lesion that could have been accurately measured in at least one dimension
  • 20 mm with conventional imaging techniques or ≥ 10 mm with spiral CT or MRI, or
  • Bone lesions: lytic or mixed (lytic + blastic) in the absence of measurable disease as defined above.
  • Adequate bone marrow, coagulation, liver and renal function.
  • ECOG performance status ≤ 2.

Exclusion Criteria

  • Patients overexpressing HER2 by local laboratory testing (IHC 3+ staining or in situ hybridization positive). Patients with IHC 2+ must have a negative in situ hybridization test.
  • Patients with only non-measurable lesions other than bone metastasis (e.g. pleural effusion, ascites).
  • Patients with more than one prior chemotherapy line for ABC. A chemotherapy line is an anticancer regimen(s) that contained at least 1 cytotoxic chemotherapy agent, given for a minimum of 21 days.
  • Previous treatment with mTOR inhibitors.
  • Known hypersensitivity to mTOR inhibitors, e.g. Sirolimus (rapamycin).
  • Patients with a known history of HIV seropositivity. Screening for HIV infection at baseline was not required.
  • Patient who were being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A
  • History of brain or other CNS metastases, including leptomeningeal metastasis.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03176238). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search